Table 4.
Clinical characteristics and outcomes by cancer treatment type
| Chemotherapy (n = 30) | Hormonotherapy (n = 25) | Targeted therapies (n = 7) | Immunotherapy (n = 11) | Surgery (n = 6) | Nononcologic patients (n = 2,527) | |
|---|---|---|---|---|---|---|
| Age, years (IQR) | 69 (56; 74) | 79 (70; 85)* (p 0.004) | 63 (57; 76) | 67 (61; 71) | 71 (57; 85) | 69 (58; 81) |
| Sex, n (%) | ||||||
| Male | 22 (68.8) | 14 (56) | 2 (28.6) | 9 (81.8) | 2 (40) | |
| Female | 10 (31.2) | 11 (44) | 5 (71.4) | 2 (18.2) | 3 (60) | |
| Ferritin, ng/mL (mean) | 2,663* (p 0.4) | 548 | 1,227 | 1,493 | 4,691 | 1,327 |
| LDH, U/L (mean) | 384 | 338 | 391 | 507 | 295 | 349 |
| Procalcitonin, ng/mL (mean) | 1.3 | 0.76 | 0.12 | 2.59 | 0.04 | 0.9 |
| C-reactive protein, mg/L (mean) | 126.96 | 93 | 95.9 | 114.99 | 106.8 | 105.4 |
| D-dimer, ng/mL (mean) | 2,583 | 1,457 | 761 | 700 | 561 | 2,544 |
| Lymphocytes, 103/µL (mean) | 1,092 | 1,032 | 999 | 797 | 1,133 | 1,220 |
| Neutrophils, 103/µL (mean) | 4,428* (p 0.49) | 5,488 | 6,620 | 5,420 | 4,652 | 6,151 |
| IL-6, pg/mL (mean) | 19 | 126 | 51.7 | 44 | 6.9 | 132 |
| IL-12, pg/mL (mean) | 0.13 | 0 | 1.8 | 1.41 | 0.24 | 0.49 |
| IL-10, pg/mL (mean) | 3.6 | 3.09 | 56.7 | 16.9 | 0.97 | 7.13 |
| IL-17, pg/mL (mean) | 0.28 | 0 | 2.99 | 0.43 | 0.26 | 1.32 |
| IL-1B, pg/mL (mean) | 0.73 | 0.09 | 0 | 0.37 | 0.21 | 0.45 |
| IL-8, pg/mL (mean) | 16.9 | 41.17 | 79.3 | 36 | 0.2 | 36.87 |
| TNF, pg/mL (mean) | 4.6 | 0.4 | 62.66 | 1.53 | 5.7 | 6.8 |
| INFg, pg/mL (mean) | 1.33 | 0 | 59.77 | 0.744 | 0.99 | 4.05 |
| Discharge from hospital, mean days | 18 | 10 | 3 | 7 | 16 | 11 |
| Death, n (%) | 14 (45.2) | 8 (32) | 0 | 4 (36.4) | 1 (16.7) | 493 (19.5) |
*
Statistically significant differences from nononcologic patients.